| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2):87-108.
|
| [2] |
Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines[J]. Proc Natl Acad Sci U S A,1987,84(24):9233-9237.
|
| [3] |
Freund A, Chauveau C, Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells[J]. Oncogene,2003,22(2):256-265.
|
| [4] |
Lin Y, Huang R, Chen L, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays[J]. Int J Cancer,2004,109 (4):507-515.
|
| [5] |
Yao C, Lin Y, Chua MS, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells[J]. Int J Cancer,2007,121(9):1949-1957.
|
| [6] |
Shao N, Chen L, Ye R, et al. The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells[J]. Biochem Bioph Res Commun,2013,431(3):535-541.
|
| [7] |
Shao N, Lu Z, Zhang Y, et al. Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway[J]. Cancer Lett,2015,364(2):165-172.
|
| [8] |
姚陈,王深明,谢丹,等. 白细胞介素-8 的表达与乳腺癌预后的关系[J]. 中华外科杂志,2006,44(13):900-903.
|
| [9] |
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(16):2784-2795.
|
| [10] |
Fridlender ZG, Albelda SM, Granot Z. Promoting metastasis:neutrophils and T cells join forces[J]. Cell Res,2015,25(7):765-766.
|
| [11] |
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition [J]. J Clin Invest,2009,119(6):1420-1428.
|
| [12] |
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer [J]. Cell,2010,140(6):883-899.
|
| [13] |
Araki S, Omori Y, Lyn D, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer [J]. Cancer Res,2007,67(14):6854-6862.
|
| [14] |
Kunz M, Hartmann A,Flory E,et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness[J]. Am J Pathol,1999,155(3):753-763.
|
| [15] |
Xiao YC, Yang ZB, Cheng XS, et al. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis[J]. Cancer Lett,2015,361(1):22-32.
|
| [16] |
Cheng XS, Li YF, Tan J, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelialmesenchymal transition[J]. Cancer Lett,2014,348(1/2):77-87.
|
| [17] |
Reis ST, Leite KR, Piovesan LF, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer[J]. BMC Urol,2012,12:18.
|
| [18] |
Slattery ML, Herrick JS, Torres-Mejia G, et al. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the breast cancer health disparities study[J]. Carcinogenesis,2014,35(8):1750-1759.
|
| [19] |
Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report[J]. Breast Cancer,2000,7(3):187-190.
|